Immutep Limited (IMM)

IO non-responder patients saved by Efti

Announcement highlights

Immutep have released updated interim data from Part B of their TACTI-D02 Phase II study, related to the efficacy of their lead asset Efti in patients with metastatic, treatment-resistant, 2nd line non-small cell lung cancer (NSCLC). The last readout from this study was back in November 2020. Immutep have released an abstract for the ESMO European Lung Cancer Congress (ELCC) in which they will present the data on April 1st to their oncology peers. Data shows that >35% of patients continue to have halted progression and/or improved tumour burden as a result of Efti addition to their previously failed pembrolizumab treatment. Importantly this effect has been maintained since the Nov 2020 readout showing sustained, durable responses (which are often hard to achieve with IO drug treatments). This data, despite being from a small patient subset (n=36), is key to highlighting the power of Efti in being able to broaden the use case for blockbuster IO drugs like Keytruda, extending their addressable market and the proportion of patient responders (including those who lack key checkpoint expression, i.e. PD-L1 negative). This is central to our investment thesis on Immutep.

Wilsons’ view

Initial analysis

Data continues to strengthens clinical case – efficacy maintained over time The data revealed in the latest Part B TACTI-002 readout continues to support the thesis that Efti is able to turn ‘cold’ tumours ‘hot’ again via its unique mechanism as an Antigen Presenting Cell (APC) activator. Data showed that the combination of Efti + pembrolizumab was able to control cancer progression (halt or improve it) in 36.1% of patients indicating that the benefit patients have received is sustained ≥12 months on (Figure 1). Whilst an ORR of 5.6% (2/36) is small on an absolute basis it is critical to understand that these patients are those that have failed/not responded to current first line SOC therapy with anti-PD-1 agents (i.e. pembrolizumab, nivolumab etc) and/or chemotherapy. This leaves these patients with limited options. Here Immutep have shown that by the addition of Efti to an anti-PD-1 agent they are able to ‘rescue’ an additional 36% of patients that would otherwise have tumour progression – which is powerful and relevant for pharma that continue to struggle with IO resistance and low overall treatment response rates (20-30%). The durability of patient responses is a significant win for Immutep confirmed by this data readout.

Figure 1. Updated data readout from TACTI-002 Part B of Efti + pembrolizumab (Keytruda) in 2nd line NSCLC PD-1/PD-L1 non-responders

Source: Immutep, Wilsons.
Importantly, this tumour stabilisation did not come at the expense of safety. The updated interim data shows safety and tolerability of the Efti + pembrolizumab combination in line with previously reported data. Two patients (5.6%) discontinued treatment due to adverse reactions. This is critical also to the future of Efti in an IO-IO combination setting, where the incremental efficacy benefit must far outweigh any additive toxicity of a second agent (i.e. Efti in this case) – which it does in this case. The same has not been seen with other combinations in the past (i.e. addition of anti-CTLA-4 agents to anti-PD-1s has led to worsened safety/tolerability profiles in some instances).

Responses achieved in cohort lacking PD-1 expression. As a reminder, the TACTI-002 Part B enrolled patients on an all-comers basis – i.e. they were not restricted to only those with positive PD-L1 checkpoint expression. It is key to note that current approvals of Keytruda are restricted to patients that express its checkpoint target (PD-1) (~65% patients max). This leaves a significant portion of patients (~35%) with no access to Keytruda in mNSCLC. The data presented today by Immutep included 13 of 36 (36%) patients with no PD-L1 expression. Being able to achieve disease control in a cohort irrespective of PD-L1 expression is important for the expansion of anti-PD-1 therapies and their addressable market.

Efti has the potential to expand the TAM for Keytruda by >30%. As we have previously assessed, we see the true value of Efti in its ability to extend and expand the addressable market for pembrolizumab (Keytruda®) – hence why it is so attractive to large anti-PD-1 players like Merck (MSD). This data shows just in one cancer indication how Efti is able to reinvigorate the immunogenic cancer response that was previously unresponsive to effectively increase the ‘responder’ patient pool for Keytruda by >35%. This brings the potential for players like MSD to a) increase the number of patients who respond to Keytruda; b) increase the spectrum of cancers that may be made more immunogenic; and c) achieve longer survival for Keytruda patients which has the ability to increase sales per patient.

Earnings implications

None. This data further solidifies our view in the attractiveness of Efti in the NSCLC indication as a potential game-changer for existing anti-PD-1 drugs such as Keytruda.

Investment view

We maintain our OVERWEIGHT rating and $0.91 per share risked PT on Immutep. As a reminder, ~55% of our risked valuation lies with the opportunity for Efti in the NSCLC indication.
Disclaimer

This document has been prepared by Wilsons. This communication is not to be disclosed in whole or part or used by any other party without Wilsons’ prior written consent. All material presented in this document, unless specifically indicated otherwise, is under copyright to Wilsons. None of the material, its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of Wilsons. This document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Wilsons to any registration or licensing requirement within such jurisdiction.

This document is being supplied to you solely for your information and no action should be taken on the basis of or in reliance on this document. To the extent that any information prepared by Wilsons contains any financial product advice, it is general advice only and has been prepared by Wilsons without reference to your objectives, financial situation or needs. You should consider the appropriateness of the advice in light of your own objectives, financial situation and needs before deciding to acquire a financial product. Please refer to Wilsons’ Financial Services Guide for more information: wilsonsadvisory.com.au/disclosures. Any person, before acting on any advice contained within this communication, should first consult with a Wilsons investment adviser to assess whether the advice within this communication is appropriate for their objectives, financial situation and needs. Those acting upon such information without advice do so entirely at their own risk.

This document provided by Wilsons is current as at the date of the issue but may be superseded by future publications. Wilsons assumes no obligation to update the information or advise on further developments relating to the company or companies covered in this document (“Companies”) or relevant financial products. Wilsons has not independently verified all of the information given in this document which is provided at a point in time and may not contain all necessary information about the Companies. Wilsons makes no warranty, express or implied, concerning any information prepared by Wilsons. Wilsons expressly disclaims (1) any implied warranty of merchantability or (2) fitness for a particular purpose, including any warranty for the use or the results of the use of any information prepared by Wilsons with respect to their correctness, quality, accuracy, completeness, reliability, performance, timeliness, or continued availability. Wilsons’ research content should be viewed as an additional investment resource, not as your sole source of information. To the fullest extent permitted by law Wilsons, its related bodies corporate and their respective officers, directors, employees or agents, disclaim any and all liabilities for any loss or damage howsoever arising in connection with the use of this document or its contents. Past performance does not necessarily indicate a financial product’s likely future performance.

This document may contain “forward-looking statements”. Forward-looking statements, opinions and estimates provided in this document are based on assumptions and contingencies which are outside the control of Wilsons and are subject to change without notice (including but not limited to economic conditions, market volatility and company-specific fundamentals), and therefore may not be realised in the future.

This report does not constitute an offer or invitation to purchase any securities and should not be relied upon in connection with any contract or commitment whatsoever.

Regulatory disclosures

Wilsons restricts research analysts from trading in securities for which they write research. Other Wilsons employees may hold interests in the company, but none of those interests are material. Wilsons further advises that at the date of this report, neither Wilsons Advisory and Stockbroking Limited or Wilsons Corporate Finance Limited have any material interests in the company.

Wilsons contact

For more information please phone: 1300 655 015 or email: publications@wilsonsadvisory.com.au